Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Arcus Biosciences (RCUS) over the last 5 years, with Q3 2025 value amounting to $106.5 million.

  • Arcus Biosciences' Shares Outstanding (Diluted Average) rose 1652.08% to $106.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.5 million, marking a year-over-year increase of 1652.08%. This contributed to the annual value of $90.1 million for FY2024, which is 2175.68% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Shares Outstanding (Diluted Average) is $106.5 million, which was up 1652.08% from $106.5 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Shares Outstanding (Diluted Average) ranged from a high of $106.5 million in Q2 2025 and a low of $71.2 million during Q1 2022
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $74.3 million (2021), whereas its average is $82.9 million.
  • As far as peak fluctuations go, Arcus Biosciences' Shares Outstanding (Diluted Average) tumbled by 270.27% in 2022, and later soared by 2445.36% in 2024.
  • Arcus Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $74.0 million in 2021, then decreased by 2.7% to $72.0 million in 2022, then rose by 2.78% to $74.0 million in 2023, then rose by 21.76% to $90.1 million in 2024, then increased by 18.2% to $106.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $106.5 million in Q3 2025, compared to $106.5 million in Q2 2025 and $98.4 million in Q1 2025.